NIPAH VIRUS
LEVELS: Highly unlikely: No controls necessary; Occupational exposure risk: Non-foodborne transmission pathway(s) that are strongly associated with occupational exposure and can lead to human infection; Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals; Prolonged disruption: Measureable negative effect on demand for more than 6 months when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); No availability: Effective vaccines not currently available in the US (or have not been developed); Highly likely: Can be eradicated using existing tools and knowledge
OVERVIEW
Nipah virus is a highly pathogenic zoonotic paramyxovirus in the genus Henipavirus that first emerged in 1998-1999 causing a major epidemic in pigs and humans in Peninsular Malaysia and Singapore. The virus is a Biosafety Level 4 (BSL-4) agent representing one of the most dangerous known zoonotic pathogens, with human case fatality rates of 40-75% depending on the outbreak. Fruit bats of the genus Pteropus are the natural reservoir, and the Malaysian outbreak is believed to have resulted from spillover to domestic pigs, which then amplified the virus and transmitted it to humans and other domestic animals including dogs, cats, and horses. In pigs, Nipah virus causes acute febrile disease with respiratory signs (notably a characteristic "barking" cough) and/or neurological signs, with variable severity from subclinical to fatal. The virus spread between Malaysian pig farms through movement of infected animals and reached Singapore through importation of pigs to abattoirs, where workers became infected. In Malaysia, 265 human cases occurred with 105 deaths (40% CFR); subsequent outbreaks in Bangladesh and India without pig involvement have had CFRs averaging 75%. The recommended response to confirmed Nipah virus infection in pigs is rapid eradication through quarantine and culling of all susceptible animals—treatment is not appropriate given the extreme zoonotic hazard. Two genotypes exist (Malaysia and Bangladesh), and vaccine candidates for pigs are in development.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
No foodborne transmission of Nipah virus from pork products to humans has been documented. Human infection during the Malaysian outbreak was associated with direct contact with infected pigs—feeding, handling, assisting with farrowing, treatment, and removal of sick or dead animals. Living on an infected farm without direct pig contact was not a significant risk factor. The Bangladesh and India outbreaks involved drinking date palm sap contaminated by bats, with subsequent human-to-human transmission, but not consumption of pork. In the Philippines outbreak, horse slaughter and consumption of horse meat were implicated, though this involved a different intermediate host. While Nipah virus infects multiple organ systems and could theoretically be present in meat, the epidemiological pattern of human cases being restricted to those with direct occupational contact with live infected pigs suggests the respiratory/droplet route is the primary transmission pathway, not foodborne exposure.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Occupational exposure risk: Non-foodborne transmission pathway(s) that are strongly associated with occupational exposure and can lead to human infection
Nipah virus presents an extreme zoonotic hazard with documented transmission from pigs to humans. In the Malaysian outbreak, most of the 265 human cases were pig farmers and others with close contact with infected pigs. The pattern of infection suggested transmission via sputum or large droplets rather than fine aerosol—coughing and loud squealing by infected pigs would facilitate this mode. Specific risk factors included feeding/handling pigs, assisting with farrowing, and treatment/removal of sick or dead pigs. Abattoir workers in Singapore processing Malaysian pigs were also infected (11 cases, 1 death). The human CFR in Malaysia was 40%. Subsequent outbreaks in Bangladesh and India (without pig involvement, occurring via bat-contaminated date palm sap and human-to-human transmission) have had CFRs averaging 75%. The Philippines outbreak in 2014 involved horses as intermediate hosts with 53% CFR. Human-to-human transmission has been documented in Bangladesh, India, and Philippines outbreaks. Given this extreme zoonotic risk, "treatment of clinically affected animals should not be considered" and "it is essential to prevent the movement of all animals and minimize human contact with potentially infected animals."
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity
Nipah virus demonstrated high contagiousness among pigs during the Malaysian outbreak, spreading rapidly within and between farms. Transmission occurs through direct and possibly airborne exposure to secretions from infected animals—virus is detected in epithelium of upper and lower respiratory tract and in oral/nasal swabs. Pigs begin shedding virus in oral and nasal swabs at 2 days post-infection, before clinical signs appear, and shedding can persist up to 3 weeks. The movement of infected pigs was the primary means of spread between farms, between Malaysian states, and internationally to Singapore. Standard biosecurity measures proved insufficient to prevent within-herd and between-herd spread during the outbreak. The virus also infected dogs, cats, and horses on affected farms, creating additional potential transmission pathways. Dogs showed high seroprevalence on infected farms; cats were susceptible and excreted virus in urine. The ultimate biosecurity failure is the wildlife reservoir—fruit bats (Pteropus species) maintain the virus enzootically and can contaminate pig environments through droppings, urine, and partially eaten fruit.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
Nipah virus infection lacks pathognomonic clinical signs in pigs. The respiratory disease with "barking" cough was considered characteristic in Malaysia but is not definitive. Clinical presentation varies by age and can be confounded by secondary infections—coinfection with classical swine fever virus and opportunistic bacteria may mask Nipah-specific signs. This may explain why Nipah virus circulated undetected in Malaysia since 1996 (per retrospective studies) before the outbreak was recognized. Differential diagnosis includes causes of sudden death in adults, respiratory disease with severe coughing, reproductive failure, and neurological disease. Laboratory confirmation requires BSL-4 containment for virus isolation. Safer diagnostic approaches include: qRT-PCR for viral RNA detection in oral/nasal swabs (positive from 2 DPI) or tissues (trigeminal ganglion, olfactory bulb, lung, spleen); immunohistochemistry on formalin-fixed tissues (multinucleated syncytial cells in respiratory epithelium and endothelium are suggestive); and serology using ELISA with recombinant antigens (antibody detectable by 10 DPI) with confirmation by virus neutralization in BSL-4 laboratory. Samples must be heat-treated (60°C for 1 hour) before serological testing to inactivate potential virus.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals
Nipah virus infection causes variable but potentially severe losses across all production stages. Clinical severity ranges from subclinical to fatal. In weaner and grower pigs, infections were frequently subclinical but acute febrile illness with respiratory signs (barking cough) and neurological signs (muscle fasciculation, weakness, paresis) also occurred; mortality in this age group was low (<5%). In sows and boars, acute death occasionally occurred with minimal prior signs or within 24 hours of onset; abortions were reported. Suckling pigs showed high mortality (though whether from primary infection or disease in sows was unclear). However, the direct production losses pale compared to the eradication costs: the recommended response to confirmed Nipah virus is "rapid eradication" through "quarantine of infected premises and culling of all susceptible animals." In Malaysia, over 1 million pigs were culled to control the outbreak. The economic impact includes: complete loss of culled animals, facility decontamination costs, business interruption during quarantine, loss of genetic progress, and rebuilding costs. Secondary impacts include loss of associated animals (dogs, cats) that may be infected.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Prolonged disruption: Measureable negative effect on demand for more than 6 months when disease occurs on one or more farms
Nipah virus is an OIE/WOAH-listed disease with severe trade implications. Detection would trigger immediate regulatory response, movement restrictions, and international trade suspension. The combination of: (1) extreme human fatality rate (40-75%); (2) demonstrated ability to spread internationally via pig movement (Malaysia to Singapore); (3) BSL-4 classification; and (4) absence of treatment or vaccine creates a scenario where trading partners would impose maximum precautionary restrictions. The Malaysian outbreak devastated the country's pig industry—over 1 million pigs culled, export markets closed, and prolonged recovery period. Consumer confidence would be severely affected given the public health implications. Even after eradication, demonstrating freedom and rebuilding trade relationships would take years. The Philippines outbreak in 2014 (involving horses rather than pigs) similarly caused significant regional concern. Any country detecting Nipah virus in its pig population would face catastrophic and prolonged market consequences.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
Nipah virus is a viral pathogen (negative-sense RNA virus, family Paramyxoviridae) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns. Two genotypes exist (Malaysia and Bangladesh) representing natural viral evolution, but this is not related to antimicrobial resistance.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
Antimicrobial treatment of Nipah virus-infected pigs is not recommended and should not be attempted given the extreme zoonotic hazard. The chapter explicitly states: "Nipah virus is a dangerous zoonotic agent and treatment of clinically affected animals should not be considered." The recommended response is rapid eradication through culling rather than treatment. Any antimicrobial use would be confined to treating secondary bacterial infections identified during outbreak investigation, representing minimal, episodic use that would not drive AMR selection pressure.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No antiviral treatments exist for Nipah virus infection in any species. More importantly, treatment of infected pigs should not be attempted due to the extreme zoonotic risk—the chapter states this explicitly. The recommended response to confirmed infection is quarantine and rapid eradication through culling of all susceptible animals on affected premises. Supportive care or treatment of secondary infections would require close human contact with infected animals, creating unacceptable transmission risk. Human cases are treated with supportive care; ribavirin has shown some benefit in observational studies but no controlled trials exist.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
No licensed vaccine exists for Nipah virus in any species. However, vaccine candidates for pigs are in development: (1) A bovine herpesvirus-4 vector expressing Nipah virus glycoproteins induced potentially protective immune responses in pigs; (2) A recombinant subunit vaccine using soluble G glycoprotein is under development; (3) The highly effective Hendra virus vaccine used in horses in Australia (based on soluble G glycoprotein) provides a model—Nipah and Hendra viruses are closely related henipaviruses and share antigenic properties, with Hendra diagnostic reagents useful for Nipah investigations. Natural infection produces neutralizing antibodies by 7-10 days post-infection, reaching titers of approximately 1:1280 by 14-16 days and providing protection against challenge. Full protection requires both neutralizing antibodies and cell-mediated immunity. These findings suggest vaccination could be effective once vaccines are developed and licensed. Vaccines could potentially be deployed in outbreak response or prophylactically in high-risk regions where pteropid bats and pig production overlap.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Highly likely: Can be eradicated using existing tools and knowledge
Nipah virus has never been detected in the United States, and eradication from domestic pigs is achievable using established protocols. Malaysia successfully eradicated Nipah virus from its pig population in 1999 through quarantine of infected premises and culling of all susceptible animals. Key factors supporting eradication: (1) No evidence of persistent infection in pigs—the possibility cannot be excluded but has not been demonstrated; (2) Pigs develop strong immunity after infection with high neutralizing antibody titers; (3) Virus shedding, while beginning before clinical signs (complicating control), is time-limited; (4) The wildlife reservoir (Pteropus fruit bats) does not occur in the continental United States—pteropid bats are found in Australia, Southeast Asia, Pacific Islands, and parts of Africa. The absence of the natural reservoir host eliminates the re-introduction pathway that would complicate long-term freedom. If Nipah virus were introduced to US pigs (potentially through illegal importation of infected animals or emergence of a related henipavirus from North American bats), eradication would follow the Malaysian model: immediate quarantine, movement restrictions, culling of all susceptible animals on affected premises, extensive surveillance, and demonstration of freedom before trade restoration.